Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer

JAMA Oncol. 2017 Jun 1;3(6):856-857. doi: 10.1001/jamaoncol.2017.0147.

Abstract

Using data from a prostate cancer registry, this study correlated HSD3B1 genotype with response to androgen-deprivation therapy in patients with prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Gene Frequency
  • Genotype
  • Germ-Line Mutation*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Multienzyme Complexes / genetics*
  • Neoplasm Metastasis
  • Pharmacogenomic Variants
  • Polymorphism, Single Nucleotide
  • Progesterone Reductase / genetics*
  • Prostatectomy
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / surgery
  • Steroid Isomerases / genetics*
  • Treatment Outcome

Substances

  • 3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase
  • Androgen Antagonists
  • Multienzyme Complexes
  • Progesterone Reductase
  • Steroid Isomerases